Company webinar

Cynata Therapeutics (ASX:CYP)

Watch our webinar with Cynata Therapeutics, featuring Managing Director and CEO Dr Kilian Kelly. A presentation followed by live Q&A with the audience.

Date
December 9, 2025
Time
Where
Online
Entry
Free
Dr Kilian Kelly
Dr Kilian Kelly
Managing Director and CEO, Cynata Therapeutics (ASX:CYP)

About the company

Cynata is commercialising Cymerus™ - a platform that produces Mesenchymal Stem Cells (MSCs) at scale. MSCs are potent immune-modulating and tissue-repairing cells, but naturally scarce in the human body. Traditional manufacturing depends on constant donors and suffers from inconsistency, potency loss, and limited scalability. Cymerus™ removes this bottleneck and unlocks true therapeutic and commercial potential.

The company has 3 clinical programs underway and major Phase 2 and Phase 3 readouts due in the next 6-9 months. Earlier clinical results already demonstrate strong safety and efficacy, giving investors a rare evidence-based confidence as they move into these pivotal late-stage milestones.

Key topics

  • The Cymerus™ platform and how it solves the MSC manufacturing bottleneck.
  • The major Phase 2 and Phase 3 clinical readouts due this financial year.
  • Evidence from previous trials demonstrating safety and efficacy.
  • Commercialisation pathways and the scale of the market opportunity.
  • How Cynata is positioned within the MSC sector and why it may be “next in line.”

Watch the recording

More webinars

All webinars →

Go beyond the presentation

Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.

Explore our services →